Search Results: "Pozen"
-
Pozen migraine drug licensed to Desitin for commercialization in Europe
The migraine headache treatment developed by Pozen (NASDAQ:POZN) now has a partner for commercialization in […]
-
How arthritis drug Vimovo could ease Pozen’s PA32540 regulatory pain
Osteoarthritis drug Vimovo‘s sales disappointed early and its U.S. prescriptions have declined as of late, […]
-
FDA concerns may limit cardiovascular approval of Pozen’s safer aspirin
Pozen (NASDAQ:POZN), now prepping to file a new drug application for its safer form of […]
-
Safer aspirin is strong in phase 3; Pozen plans 3Q NDA filing
The delayed-release aspirin compound that Pozen (NASDAQ:POZN) has developed to protect against cardiovascular disease showed […]
-
Aspirin reimagined and Pozen’s new drug partnership possibilities
As drug partnering auditions go, Pozen (NASDAQ:POZN) has played this role before: The small drug […]
-
Aspirin alternative to ward off cardiovascular disease could improve patient adherence
Low-dose aspirin or baby aspirin has been widely prescribed as a prevention measure against heart […]
-
Specialty pharmaceutical maker raising $7.7 million for safer, longer-lasting aspirin
Reducing the side effects and improving compliance in the millions of people who take aspirin regularly is the goal of a pharmaceutical company raising up to $7.7 million in anticipation of a 2013 NDA filing.
-
GI-safe aspirin leads PLx’s pipeline of improved safety NSAIDs
Nonsteroidal anti-inflammatory drugs are one of the most prescribed drug classes, but their gastrointestinal toxicity […]
-
How arthritis drug Vimovo shaped POZN’s strategy on its heart drug
Arthritis represents a large medical need but it is served by several products that carry […]
-
Three lessons from two deals: POZN’s takeaways from drug partnerships
Pozen (NASDAQ:POZN) CEO John Platchetka likens the drug partnering process to a relay race. One […]
-
Physician satisfaction takes center of pharma’s new drug marketing practices
GlaxoSmithKline (NYSE:GSK) isn’t the only big drug company overhauling how pharmaceutical sales representatives talk to […]